Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Gene Therapy Promise | Benitec Biopharma's BB-301 shows encouraging results in OPMD trial, with consistent improvements in swallowing capability and patient-reported outcomes |
Clinical Milestones | Explore the company's progress as it advances to the high-dose cohort, with potential updates expected in Q4 2025 that could significantly impact stock performance |
Financial Fortitude | Learn about Benitec's robust liquidity position, with a current ratio of 14.8 and recent $30 million capital raise, supporting ongoing clinical development |
Market Potential | Analyst price targets range from $17 to $35, suggesting significant upside potential as Benitec's gene therapy platform shows promise for treating rare diseases |
Metrics to compare | BNTC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBNTCPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.6x | −1.8x | −0.7x | |
PEG Ratio | −0.80 | 0.09 | 0.00 | |
Price/Book | 4.5x | 7.2x | 2.6x | |
Price / LTM Sales | - | 49.1x | 3.4x | |
Upside (Analyst Target) | 78.3% | 247.5% | 37.3% | |
Fair Value Upside | Unlock | 11.0% | 5.2% | Unlock |